Product Information
SIROLIMUS 1 MG TABLET is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.7230 per EA under NDC 68462068301. Its NADAC has been published 308 times since Nov 11, 2020.
FDA first approved this application on Oct 16, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1 mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462068301
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SIROLIMUSApproval Type
Generic (ANDA)
FDA Application
ANDA208691FDA Approved
10/16/2020
TE Code
AB
On Market Since
10/16/2020
Pharmacological Classes
Price Statistics
The NADAC for SIROLIMUS 1 MG TABLET has been published 308 times since Nov 11, 2020, and over the history we have for it it has declined 89.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7230 per EA |
|---|---|
| All-time high | $7.3204 (Feb 10, 2021) |
| All-time low | $0.7230 (Sep 23, 2026) |
| 52-week high | $1.4779 |
| 52-week low | $0.7230 |
| Median price | $2.7065 |
| Average price | $3.5163 |
| Largest weekly change | -38.5% (Nov 20, 2024) |
| Weeks tracked | 308 |
| Tracking since | Nov 11, 2020 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sirolimus market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SIROLIMUS 1 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SIROLIMUS 1 MG TABLET, manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.7230 per EA (NDC 68462068301), effective Sep 30, 2026.
How has the price of SIROLIMUS 1 MG TABLET changed over time?
Over the history we have for it, the NADAC for SIROLIMUS 1 MG TABLET has declined 89.6%. It has been tracked across 308 weekly CMS publications since Nov 11, 2020.
What are the highest and lowest recorded NADAC prices for SIROLIMUS 1 MG TABLET?
Since Nov 11, 2020, the NADAC for SIROLIMUS 1 MG TABLET has ranged from a low of $0.7230 (Sep 23, 2026) to a high of $7.3204 (Feb 10, 2021), with a median of $2.7065 per EA.
Are there cheaper alternatives to SIROLIMUS 1 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as SIROLIMUS 1 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures SIROLIMUS 1 MG TABLET?
SIROLIMUS 1 MG TABLET (NDC 68462068301) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.